Biosimilars Market By Product Type (Monoclonal Antibodies, Recombinant Proteins, Erythropoietin, Insulin, Growth Hormones, Granulocyte Colony-Stimulating Factor (G-CSF)), By Application (Oncology, Autoimmune Diseases, Diabetes, Growth Disorders, Hematology, Infectious Diseases), By End-User (Hospitals, Pharmaceutical Companies, Biotech Companies, Research Institutes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Biosimilars Market was valued at USD 22.2 billion in 2023 and will surpass USD 69.0 billion by 2030; growing at a CAGR of 17.6% during 2024 - 2030.

The global biosimilars market has experienced remarkable growth due to the increasing demand for cost-effective alternatives to reference biologics. Among the different product types in the biosimilars market, monoclonal antibodies (mAbs) have emerged as the largest segment. These biologic drugs are highly effective in treating various diseases, particularly cancers and autoimmune disorders, by targeting specific antigens. Their broad application and proven efficacy have made monoclonal antibodies a cornerstone in biosimilar development, driving their widespread use across global markets.

Monoclonal antibodies offer significant clinical benefits, such as higher specificity and fewer side effects compared to conventional treatments, making them a preferred choice in treating complex diseases. The ability to replicate these drugs as biosimilars has resulted in lower healthcare costs and expanded access to life-saving treatments. The growing prevalence of cancer and autoimmune diseases continues to drive the demand for monoclonal antibody biosimilars, which have been adopted widely in markets such as North America and Europe, contributing to the growth of this segment.

Oncology Segment is Fastest Growing Due to Rising Cancer Incidences and Cost-Effective Alternatives

The oncology segment is experiencing the fastest growth within the biosimilars market, primarily due to the rising incidence of cancer worldwide and the growing need for affordable treatment options. Cancer therapies, particularly biologics, are among the most expensive treatments, which has spurred the development and adoption of biosimilars. With oncology being one of the leading therapeutic areas, the growing patient population and the increasing demand for accessible cancer treatments are fueling the rapid growth of biosimilar products in this field.

Biosimilars for oncology drugs, particularly monoclonal antibodies, have been gaining traction due to their efficacy in targeting cancer cells with fewer side effects than traditional chemotherapy. The introduction of biosimilars for cancer drugs not only makes treatment more affordable but also expands the options available to patients globally. The oncology biosimilars segment is poised for significant expansion, especially with the ongoing development of biosimilars for newer cancer therapies, offering more competitive pricing while maintaining high treatment standards.

Hospitals Segment is Largest End-User Due to High Demand for Advanced Treatment Options

In the biosimilars market, the hospitals segment stands out as the largest end-user, accounting for the bulk of biosimilar drug demand. Hospitals serve as the primary setting for administering complex treatments like monoclonal antibodies and recombinant proteins, especially for cancer and autoimmune diseases. The significant need for specialized care and access to a broad range of biologic therapies in hospital settings has driven the large-scale adoption of biosimilars in hospitals across the globe.

Hospitals provide an ideal environment for administering biologic treatments that require careful monitoring and management, especially for critically ill patients. The availability of biosimilars in hospitals enhances treatment access by offering affordable alternatives to expensive branded biologics, which is especially important in regions with large patient populations but limited healthcare budgets. As hospitals continue to expand their oncology and autoimmune disease treatment capabilities, the demand for biosimilars is expected to grow steadily within this segment.

Online Pharmacies Segment is Fastest Growing Due to Increased Consumer Preference for Convenience

The online pharmacies segment is the fastest-growing distribution channel for biosimilars, driven by the increasing consumer preference for convenience and accessibility in purchasing medications. As digital health solutions gain momentum, online pharmacies have become a popular platform for buying not only over-the-counter drugs but also prescription medications, including biosimilars. With advancements in e-commerce and the growing adoption of telemedicine, more patients are turning to online platforms to obtain their biosimilar medications, especially in remote or underserved areas.

The convenience and affordability offered by online pharmacies make them an attractive option for consumers looking to access biosimilars without the logistical challenges of visiting a physical pharmacy. This trend is particularly prominent in regions like North America and Europe, where digital health infrastructures are well-established. As online pharmacies continue to provide more comprehensive services and streamline the purchasing process, the segment is expected to see rapid growth in the coming years.

North America is the Largest Region Due to Advanced Healthcare Infrastructure and Regulatory Support

North America remains the largest region in the global biosimilars market, owing to its advanced healthcare infrastructure, regulatory support, and high adoption rate of biosimilars. The U.S., in particular, has played a pivotal role in the growth of the biosimilars market due to the established regulatory pathways created by the FDA for biosimilar approval. These regulations have paved the way for more biosimilars to enter the market, providing healthcare providers with cost-effective alternatives to expensive biologics.

Furthermore, the large-scale healthcare spending and the high prevalence of chronic diseases, including cancer and autoimmune disorders, continue to drive the demand for biosimilars in North America. The region's strong healthcare system, coupled with the increasing availability of biosimilars, ensures that more patients can benefit from affordable and effective biologic treatments. As the market matures and more biosimilars gain regulatory approval, North America will continue to dominate the global market.

Leading Companies and Competitive Landscape

The competitive landscape in the biosimilars market is characterized by the presence of both large pharmaceutical companies and specialized biotech firms. Leading companies such as Amgen, Sandoz, Pfizer, and Biocon dominate the market with an extensive portfolio of biosimilar products, primarily focused on oncology, autoimmune diseases, and other therapeutic areas. These companies have robust pipelines of biosimilars, driven by extensive research and development, and their established global presence ensures widespread distribution of biosimilar drugs.

In addition to the global pharmaceutical giants, smaller biotech firms and emerging players are increasingly entering the market with new biosimilar products. The competition is fierce, as companies strive to capture market share by offering high-quality biosimilars at competitive prices. Mergers and acquisitions (M&A) are also common, with larger companies acquiring smaller biotech firms to expand their biosimilar portfolios. The market's growth potential and the increasing acceptance of biosimilars by healthcare providers are expected to foster an environment of innovation and strategic collaboration.

Recent Developments:

• Amgen announced the launch of a biosimilar to a blockbuster cancer biologic in 2024. This move expands their oncology portfolio and provides more affordable treatment options to cancer patients.
• Sandoz received FDA approval for its biosimilar insulin in 2024, offering a more cost-effective alternative to the existing insulin brands, benefiting patients with diabetes.
• Celltrion launched a new biosimilar monoclonal antibody in Europe in late 2023, targeting a common autoimmune disease, further strengthening its position in the biosimilars market.
• In a strategic acquisition, Teva Pharmaceuticals acquired a leading biosimilar portfolio from a European biotech firm in early 2024, expanding its biosimilars offerings and market share.
• Biocon and Mylan (now Viatris) announced a partnership in 2023 to develop and launch a biosimilar for a leading cancer drug. The collaboration is expected to provide cost-effective treatments to a broader patient population.

List of Leading Companies:

• Amgen Inc.
• Sandoz International GmbH
• Pfizer Inc.
• Biocon Limited
• Celltrion Inc.
• Samsung Bioepis
• Mylan N.V. (Now Viatris)
• Eli Lilly and Co.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• AbbVie Inc.
• Merck & Co., Inc.
• Boehringer Ingelheim GmbH
• Stada Arzneimittel AG
• Fresenius Kabi AG

Report Scope: